THBD and COVID-19: Marked coagulation derangements have been reported in a single-center cross-sectional study by Goshua et al. (88) who assessed markers of endothelial cell and platelet activation, namely circulating von Willebrand factor (vWF), soluble P-selectin and soluble thrombomodulin, in critically and non-critically ill COVID-19 patients.